AdJane Reports First Clinical Validation of its OMV Vaccine Platform Inducing Mucosal Immunity in Humans
Phase I results provide platform-level validation supporting AdJane’s broader development programs in pandemic preparedness, respiratory infectious diseases and antimicrobial resistance DELFT, Netherlands, July 1, 2026 /PRNewswire/ — AdJane, a clinical-stage vaccine platform company
